Ablynx raises $200m in Nasdaq listing after drug success

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity

Ablynx raises $200m in Nasdaq listing after drug success

Sam Kerr
October 24, 2017 03:30 PM
PA-Nasdaq
The Facebook Inc. logo is displayed with price valuations on monitors during trading at the Nasdaq MarketSite in New York on May 18, 2012. Facebook Inc. rose in its trading debut following a record initial public offering that made the social network more costly than almost every company in the Standard & Poor's 500 Index. Photo by Dennis Van Tine/ABACAUSA.COM | Dennis Van Tine/ABACA USA/PA Images

Ablynx, the Belgian biopharmaceutical firm, has raised $200m through a second listing in the US, following positive momentum in the development of a new drug designed to combat a life-threatening blood clotting disorder.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP MorganEquityBank of AmericaUnited StatesAmericasEuropeFollow-ons and Rights issuesBelgiumNorth AmericaEMEAJefferies LLC
SK
Sam Kerr
Gift this article